血小板因子4(PF4)检测试剂盒(化学发光免疫分析法)
CLIA Kit for Platelet Factor 4 (PF4)
CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact
- 编号SCA172Mu
- 物种Mus musculus (Mouse，小鼠) 相同的名称，不同的物种。
- 实验方法双抗夹心
- 反应时长2h, 40min
- 检测范围2.74-2,000pg/mL
- 灵敏度最小可检测剂量小于等于0.99pg/mL.
- 样本类型Serum, platelet-poor plasma and cell culture supernates
- 下载 英文说明书 中文说明书
- 规格 48T96T 96T*5 96T*10 96T*100
- 价格 ¥ 3629 ¥ 5184 ¥ 23328 ¥ 44064 ¥ 362880
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
实验结果图
-
标准曲线图
-
通过ISO 9001、ISO 13485质量体系认证
特异性
本试剂盒用于检测血小板因子4(PF4)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的血小板因子4(PF4)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 90-99 | 95 |
| EDTA plasma(n=5) | 98-105 | 102 |
| heparin plasma(n=5) | 85-102 | 97 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的血小板因子4(PF4)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中血小板因子4(PF4)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-102% | 95-103% | 83-97% | 80-103% |
| EDTA plasma(n=5) | 85-97% | 87-103% | 86-101% | 84-103% |
| heparin plasma(n=5) | 80-96% | 90-99% | 80-101% | 90-103% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备；
2. 加样（标准品及样本）100µL，37°C孵育1小时；
3. 吸弃，加检测溶液A100μL，37°C孵育1小时；
4. 洗板3次；
5. 加检测溶液B100µL，37°C孵育30分钟；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分钟；
8. 读数。
实验原理
将血小板因子4(PF4)抗体包被于96孔微孔板中，制成固相载体，向微孔中分别加入标准品或标本，其中的血小板因子4(PF4)与连接于固相载体上的抗体结合，然后加入生物素化的血小板因子4(PF4)抗体，将未结合的生物素化抗体洗净后，加入HRP标记的亲和素，再次彻底洗涤后加入底物。加入底物后会产生辉光型光信号。发射光强度和样品中的血小板因子4(PF4)呈正相关。用化学发光仪测定相对光单位（RLU），计算样品浓度。
增值服务
相关产品
| 编号 | 适用物种：Mus musculus (Mouse，小鼠) | 应用(仅供研究使用，不用于临床诊断！) |
| APA172Mu01 | 血小板因子4(PF4)活性蛋白 | Cell culture; Activity Assays. |
| RPA172Mu01 | 血小板因子4(PF4)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA172Mu02 | 血小板因子4(PF4)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA172Mu01 | 血小板因子4(PF4)多克隆抗体 | WB; IHC; ICC; IP. |
| PAA172Mu02 | 血小板因子4(PF4)多克隆抗体 | WB; IHC; ICC; IP. |
| LAA172Mu71 | 血小板因子4(PF4)多克隆抗体(生物素标记) | WB; IHC; ICC. |
| LAA172Mu81 | 血小板因子4(PF4)多克隆抗体(异硫氰酸荧光素标记) | WB; IHC; ICC; IF. |
| SEA172Mu | 血小板因子4(PF4)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA172Mu | 血小板因子4(PF4)检测试剂盒(化学发光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA172Mu | 血小板因子4(PF4)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
| KSA172Mu01 | 血小板因子4(PF4)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". |
参考文献
| 杂志 | 参考文献 |
| Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics | Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats [PubMed: 20601223] |
| Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation [PubMed: 22899170] |
| PLoS One | Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation [PubMed: PMC3608633] |
| Diving and Hyperbaric Medicine | Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompression [Pubmed:25311322] |
| Journal of Functional Foods | A Phellinus baumii–based supplement containing Salvia miltiorrhiza Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro and in vivo [science:S1756464616300676] |
| Plos one | Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury [pubmed:27583400] |
| international journal of molecular sciences | Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation. [pubmed:28272338] |
| Experimental and Therapeutic Medicine | Feasibility of improving platelet‑rich plasma therapy by using chitosan with high platelet activation ability [pubmed:28450960] |
| Reproductive Toxicology | Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats [Pubmed: 30528429] |
| INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation [Pubmed: 30857843] |
| Available at SSRN 3335365 | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers [] |
| journal of biotechnology | Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes Hemostasis [Pubmed: 30927490] |
| Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation [] |
| journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers [Pubmed: 32812629] |
| Marine Drugs | The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents [Pubmed: 31533230] |
| Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices [Pubmed: 31838449] |
| Nat Commun | The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets [34099640] |
| Vaccine | The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats [Pubmed:35183388] |